Monitoring minimal residual disease in the bone marrow using next generation sequencing

Publication date: Available online 17 January 2020Source: Best Practice &Research Clinical HaematologyAuthor(s): Even H. Rustad, Eileen M. BoyleAbstractAchieving minimal residual disease (MRD) negativity in the bone marrow is one of the strongest prognostic factors in multiple myeloma. Consequently, MRD testing is routinely performed in clinical trials and moving towards standard of care. This review focuses on the role of next generation sequencing (NGS) of tumor-specific immunoglobulin V(D)J sequences for MRD tracking. The immunoglobulin variable regions are ideal targets for tracking, because every tumor cell shares an identical gene sequence, which is stable over time and generally distinct from the immunoglobulin sequences of normal B-cells. Several excellent assays for NGS-based MRD testing are available, both commercial and community-based, including one that is FDA-approved. These assays can achieve the gold standard analytical sensitivity of one tumor cell per million (10-6), requiring a minimum input of 3 million bone marrow cells. On-going clinical trials will outline how MRD testing should be used to inform dynamic risk-adopted therapy.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research

Related Links:

Condition:   Multiple Myeloma Interventions:   Drug: CPI-444;   Drug: daratumumab Sponsor:   Corvus Pharmaceuticals, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionHigh-dose chemotherapy and autologous stem cell transplant using TBC conditioning for both PCNSL and secondary CNS non-Hodgkin lymphoma appears to have encouraging long term efficacy with manageable side effects.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThe combination of everolimus and bendamustine appeared to be well-tolerated and relatively efficacious.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionIn this cohort of ESHL patients who responded completely to frontline therapy, the relapse rate was low. Routine imaging surveillance lacks clinical benefit in this patient population.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 19 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Vasu Saini, Aditi Dhir, Ariana W. Rudnick, Joshua Lukas, Karlo J. Lizarraga, Jason Margolesky, Deborah O. Heros, James E. HoffmanAbstractParaneoplastic neurologic syndromes are rare but well described presentation of certain malignancies in both children and adults. Cerebellar dysfunction is a common paraneoplastic presentation and has been previously reported in association with small cell lung cancer, breast cancers, ovarian tumors, renal cell carcinoma, follicular lymphoma, and Hodgkin’s lymphoma. There are ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Bone Marrow Transplantation, Published online: 21 February 2020; doi:10.1038/s41409-020-0832-6Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Condition:   Multiple Myeloma Intervention:   Drug: Renalidomide, Velcade, Dexamethasone Sponsor:   Samsung Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Intervention:   Drug: Renalidomide, Velcade, Dexamethasone Sponsor:   Samsung Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsAmyloidosis is an uncommon finding in patients with multiple myeloma, especially in younger individuals.
Source: Arab Journal of Gastroenterology - Category: Gastroenterology Source Type: research
(American Association for Cancer Research) The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Clinical Trials | Genetics | Hematology | Myeloma